Aptevo Therapeutics Inc. (APVO) Reaches $4.34 After 4.00% Down Move; Muzinich & Company Has Cut By $7.66 Million Its Tcp Capital (TCPC) Stake

April 17, 2018 - By Adrian Mccoy

The stock of Aptevo Therapeutics Inc. (NASDAQ:APVO) is a huge mover today! The stock decreased 2.69% or $0.12 during the last trading session, reaching $4.34. About 98,823 shares traded. Aptevo Therapeutics Inc. (NASDAQ:APVO) has risen 72.19% since April 17, 2017 and is uptrending. It has outperformed by 60.64% the S&P500.The move comes after 7 months negative chart setup for the $91.63 million company. It was reported on Apr, 17 by Barchart.com. We have $4.17 PT which if reached, will make NASDAQ:APVO worth $3.67 million less.

Muzinich & Company decreased Tcp Capital Corp (TCPC) stake by 18.34% reported in 2017Q4 SEC filing. Muzinich & Company sold 510,441 shares as Tcp Capital Corp (TCPC)’s stock declined 9.74%. The Muzinich & Company holds 2.27 million shares with $34.74M value, down from 2.78M last quarter. Tcp Capital Corp now has $842.69M valuation. The stock increased 0.21% or $0.03 during the last trading session, reaching $14.32. About 66,327 shares traded. TCP Capital Corp. (NASDAQ:TCPC) has declined 17.80% since April 17, 2017 and is downtrending. It has underperformed by 29.35% the S&P500.

Among 7 analysts covering TCP Capital (NASDAQ:TCPC), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. TCP Capital had 16 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Wednesday, August 17 by Citigroup. Deutsche Bank upgraded the stock to “Buy” rating in Thursday, May 11 report. Deutsche Bank maintained TCP Capital Corp. (NASDAQ:TCPC) rating on Saturday, August 22. Deutsche Bank has “Hold” rating and $16.5 target. Oppenheimer maintained TCP Capital Corp. (NASDAQ:TCPC) on Friday, August 7 with “Outperform” rating. Keefe Bruyette & Woods maintained TCP Capital Corp. (NASDAQ:TCPC) rating on Thursday, October 5. Keefe Bruyette & Woods has “Buy” rating and $18.0 target. On Wednesday, February 28 the stock rating was maintained by Wells Fargo with “Outperform”. As per Thursday, March 1, the company rating was maintained by JMP Securities. The firm earned “Market Outperform” rating on Wednesday, August 10 by JMP Securities. The stock of TCP Capital Corp. (NASDAQ:TCPC) earned “Buy” rating by Keefe Bruyette & Woods on Wednesday, May 31. Oppenheimer maintained the stock with “Buy” rating in Thursday, August 3 report.

Analysts await TCP Capital Corp. (NASDAQ:TCPC) to report earnings on May, 9 before the open. They expect $0.39 EPS, down 17.02% or $0.08 from last year’s $0.47 per share. TCPC’s profit will be $22.95 million for 9.18 P/E if the $0.39 EPS becomes a reality. After $0.50 actual EPS reported by TCP Capital Corp. for the previous quarter, Wall Street now forecasts -22.00% negative EPS growth.

Since January 30, 2018, it had 7 buys, and 0 selling transactions for $486,770 activity. $73,039 worth of TCP Capital Corp. (NASDAQ:TCPC) shares were bought by HOLDSWORTH MARK. The insider Vig Rajneesh bought 5,000 shares worth $75,322. 9,000 shares valued at $137,464 were bought by LEVKOWITZ HOWARD on Tuesday, January 30. On Tuesday, January 30 the insider CORBET KATHLEEN A bought $38,042. $14,230 worth of TCP Capital Corp. (NASDAQ:TCPC) was bought by DRAUT ERIC JOHN on Monday, February 5. Wruble Brian F bought 5,000 shares worth $76,300.

Investors sentiment decreased to 0.96 in 2017 Q4. Its down 0.23, from 1.19 in 2017Q3. It dropped, as 11 investors sold TCPC shares while 34 reduced holdings. 17 funds opened positions while 26 raised stakes. 27.45 million shares or 2.70% less from 28.22 million shares in 2017Q3 were reported. Kennedy Cap stated it has 316,024 shares or 0.09% of all its holdings. Hightower Advisors holds 11,228 shares or 0% of its portfolio. Guggenheim Llc accumulated 0.02% or 546,494 shares. Trexquant Investment Limited Partnership holds 0.03% in TCP Capital Corp. (NASDAQ:TCPC) or 17,077 shares. Greenwich Investment Management owns 0.23% invested in TCP Capital Corp. (NASDAQ:TCPC) for 10,475 shares. Morgan Stanley stated it has 84,877 shares or 0% of all its holdings. 453,342 were reported by Ares Mngmt Ltd Limited Liability Company. Regions Fincl holds 0% or 500 shares in its portfolio. Vaughan Nelson Investment Management Lp accumulated 0.57% or 3.20 million shares. Van Eck Associate Corporation owns 372,765 shares. Ngam Advisors Limited Partnership reported 260,494 shares. 9,289 are held by Glenmede Trust Na. Covington Cap Mngmt reported 62,727 shares stake. Legal & General Public Ltd Company invested in 181,984 shares or 0% of the stock. Capstone Inv Advisors Ltd Llc has 32,238 shares for 0.01% of their portfolio.

Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. The company has market cap of $91.63 million. The Company’s marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. It has a 13.27 P/E ratio. The companyÂ’s marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals.

Analysts await Aptevo Therapeutics Inc. (NASDAQ:APVO) to report earnings on May, 11. They expect $-0.56 earnings per share, down 16.67% or $0.08 from last year’s $-0.48 per share.

TCP Capital Corp. (NASDAQ:TCPC) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: